BEBT-508 is a small nucleic acid (siRNA) drug. Several antisense nucleic acid and siRNA drugs have already been approved for market overseas. The company's focus is on significant disease areas such as metabolic disorders and genetic diseases. Leveraging its proprietary innovative technology in small nucleic acid drug delivery and siRNA chemical modification, the company is developing globally pioneering drugs (First-in-Class) urgently needed for clinical use and innovative drugs to address unmet medical needs. BEBT-508 is currently in the new drug discovery phase and is proposed to be developed for Non-alcoholic fatty liver disease.

Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号